Serial 97844288
Live / Registered — Registered (as of 31 Dec 2024)
What this means for you
Registered since 31 Dec 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97844288
- Registration number
- 7635116
- Mark type
- Design / logo
- Filed
- 17 Mar 2023
- Published for opposition
- 30 Jan 2024
- Registered
- 31 Dec 2024
- Attorney of record
- Danny M. Awdeh
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for modulating neuropeptides and G-protein coupled receptors (GPCRs); pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine related diseases; pharmaceutical preparations for targeting neuropeptide receptors; pharmaceutical preparations for the treatment of cancer, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, carcinoid syndrome, congenital adrenal hyperplasia, hypercalcemia, chronic pain, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; therapeutic preparations for the treatment of ocular diseases and disorders, metabolic diseases and disorders, hormonal diseases and disorders, reproductive diseases and disorders, bone diseases and disorders, digestive diseases and disorders, gastroenterological diseases and disorders, and thyroid diseases and disorders
- Class 042 — Scientific and technological services: Medical research services; scientific research and development; pharmaceutical research and development; therapeutic research and development, namely, research and development of therapeutic preparations; research and development in the field of oncology; medical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; pharmaceutical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, and chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; therapeutic research, namely, research of therapeutic preparations for ocular diseases and disorders, metabolic diseases and disorders, hormonal diseases and disorders, reproductive diseases and disorders, bone diseases and disorders, digestive diseases and disorders, gastroenterological diseases and disorders, and thyroid diseases and disorders; providing medical and scientific research information in the fields of pharmaceuticals and therapeutics
Owner
- Crinetics Pharmaceuticals, Inc., San Diego, CA, US
- Crinetics Pharmaceuticals, Inc., San Diego, CA, US
- Crinetics Pharmaceuticals, Inc., San Diego, CA, US
Prosecution history
- 31 Dec 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 31 Dec 2024 — REGISTERED-PRINCIPAL REGISTER
- 09 Dec 2024 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 09 Dec 2024 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 13 Nov 2024 — STATEMENT OF USE PROCESSING COMPLETE
- 12 Sept 2024 — USE AMENDMENT FILED
- 13 Nov 2024 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 12 Sept 2024 — TEAS STATEMENT OF USE RECEIVED
- 12 Sept 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Sept 2024 — SOU EXTENSION 1 GRANTED
- 12 Sept 2024 — SOU EXTENSION 1 FILED
- 12 Sept 2024 — SOU TEAS EXTENSION RECEIVED
- 26 Mar 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 28 Feb 2024 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 28 Feb 2024 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED